A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

• Age \> 18 years, with residual invasive triple negative breast cancer (TNBC) in the breast or lymph nodes after neoadjuvant therapy and surgery:

⁃ TNBC criteria for the study is defined as estrogen receptor (ER) and progesterone receptor (PR) \< 10%, human epidermal growth factor receptor 2 (HER2)-negative per American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry (IHC) and/or in situ hybridization (ISH)).

• Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery.

• Submission of both pre-neoadjuvant treatment diagnostic biopsy and resected residual invasive disease tissue.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

• Individuals must have received appropriate radiotherapy and have recovered prior to starting study treatment.

• Adequate organ function.